High-Sensitivity C-Reactive Protein and Statin Initiation

Angiology. 2015 Jul;66(6):503-7. doi: 10.1177/0003319714543000. Epub 2014 Jul 22.

Abstract

The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.

Keywords: C-reactive protein; biomarker; cardiovascular disease; high-sensitivity C-reactive protein; inflammation; statins.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers / blood
  • C-Reactive Protein / analysis*
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Dyslipidemias / blood
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Inflammation / blood*
  • Inflammation / complications
  • Inflammation Mediators / blood*
  • Practice Guidelines as Topic
  • Predictive Value of Tests
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Inflammation Mediators
  • C-Reactive Protein